arrow
J

Julia Garcia-Diaz

Ochsner Clinic Foundation
H指数:37
被引数:6,563

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections

大肠杆菌ST131驱动了大肠杆菌血流感染中使用碳青霉烯类药物。

2026-03-060
PRE
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

Ridinilazole与万古霉素治疗艰难梭菌感染的随机,双盲,3期安全性和有效性研究: 微生物组和代谢组与反应相关的临床结果

2024-02-028
OAAI
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter Baumannii Among Patients From Different Global Regions

全球不同地区耐碳青霉烯类鲍曼不动杆菌的临床转归及细菌特征

2023-09-2031
PRE
Phase 2, randomized, double-blind, placebo-controlled multi- center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia
2023-07-014
OAAI
Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA™) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection

粪便微生物群的安全性和有效性的回顾性分析,Live-jslm (REBYOTA™) 在执法自由裁量权下对艰难梭菌感染患者进行管理

2023-03-3111
OAAI
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022)
DRUGS
IF14.4
2022-11-071
OAAI
Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study

头孢曲松耐药对大肠埃希菌血流感染的临床影响: 一项多中心前瞻性队列研究

2022-10-278
OAAI
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

RBX2660在PUNCH CD3中的疗效和安全性,这是一项III期,随机,双盲,安慰剂对照试验,采用贝叶斯主要分析来预防复发性艰难梭菌感染

DRUGS
IF14.4
2022-10-26131
OAAI
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

Tocilizumab在新型冠状病毒肺炎肺炎住院患者中的疗效,安全性,病毒清除和抗体反应: 一项随机对照试验 (COVACTA)

2022-05-0119
OAAI
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Tocilizumab和remdesivir在严重新型冠状病毒肺炎肺炎住院患者中的应用: 一项随机临床试验

2021-10-0591
OAAI
Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells
2021-07-1447
OAAI
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
2021-01-07880
OAAI
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
2020-06-01209
OAAI